Amerise Biosciences Limited (BOM:531681)
India · Delayed Price · Currency is INR 0.8300
-0.0200 (-2.35%)
At close: Aug 21, 2026
Amerise Biosciences Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Assets
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | - | 5.92 | 0.22 | 0.21 | 0.14 | 0.13 |
Cash & Short-Term Investments | 5.92 | 5.92 | 0.22 | 0.21 | 0.14 | 0.13 |
Cash Growth | 2566.22% | 2566.22% | 5.21% | 55.15% | 4.61% | -32.69% |
Receivables | - | - | - | - | - | 62.17 |
Other Current Assets | - | 0.2 | 0.05 | 0.02 | - | -0 |
Total Current Assets | - | 6.12 | 0.27 | 0.23 | 0.14 | 62.29 |
Long-Term Investments | - | 37.7 | 23.81 | 22.65 | 45.66 | 46.91 |
Other Long-Term Assets | - | - | - | - | - | -0 |
Total Assets | - | 74.22 | 84.63 | 53.9 | 56.47 | 119.88 |
Liabilities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Accounts Payable | - | - | - | - | - | 62.66 |
Current Income Taxes Payable | - | - | 0.02 | - | - | - |
Other Current Liabilities | - | 20.26 | 30.82 | 0.16 | 0.37 | 0.01 |
Total Current Liabilities | - | 20.26 | 30.84 | 0.16 | 0.37 | 62.67 |
Long-Term Debt | - | - | - | - | 0.9 | 0.83 |
Other Long-Term Liabilities | - | - | - | - | - | -0 |
Total Liabilities | - | 20.26 | 30.84 | 0.16 | 1.27 | 63.49 |
Shareholders' Equity
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | - | 66.07 | 66.07 | 66.07 | 66.07 | 66.07 |
Retained Earnings | - | - | -13.09 | -13.14 | -11.68 | -10.49 |
Comprehensive Income & Other | - | -12.11 | 0.81 | 0.81 | 0.81 | 0.81 |
Shareholders' Equity | 53.96 | 53.96 | 53.8 | 53.74 | 55.2 | 56.39 |
Total Liabilities & Equity | - | 74.22 | 84.63 | 53.9 | 56.47 | 119.88 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Total Debt | - | - | - | - | 0.9 | 0.83 |
Net Cash (Debt) | 5.92 | 5.92 | 0.22 | 0.21 | -0.76 | -0.7 |
Net Cash Growth | 2566.22% | 2566.22% | 5.21% | - | - | - |
Net Cash Per Share | 0.07 | 0.10 | 0.00 | 0.00 | -0.01 | -0.01 |
Filing Date Shares Outstanding | 81.4 | 61.3 | 66.07 | 66.07 | 66.07 | 66.07 |
Total Common Shares Outstanding | 81.4 | 61.3 | 66.07 | 66.07 | 66.07 | 66.07 |
Working Capital | - | -14.14 | -30.57 | 0.07 | -0.23 | -0.37 |
Book Value Per Share | 0.88 | 0.88 | 0.81 | 0.81 | 0.84 | 0.85 |
Tangible Book Value | 53.96 | 53.96 | 53.8 | 53.74 | 55.2 | 56.39 |
Tangible Book Value Per Share | 0.88 | 0.88 | 0.81 | 0.81 | 0.84 | 0.85 |